Posted by Michael Wonder on 02 Oct 2024
Elacestrant dihydrochloride for the treatment of patients with advanced, oestrogen receptor positive, ESR1 mutation positive, HER2 negative breast cancer after at least one endocrine treatment
1 October 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the use of elacestrant dihydrochloride in the NHS in England.
Elacestrant dihydrochloride is not recommended for the treatment of locally advanced or metastatic, oestrogen receptor positive, ESR1 mutation positive, HER2 negative, breast cancer that has progressed after at least one line of endocrine therapy including a cyclin-dependent kinase (CDK) 4 and 6 inhibitor in women, trans men and non-binary people after menopause and men.
